Early change from intravenous to oral antibiotics: Switch therapy;Vroege omzetting van intraveneuze naar orale antibiotica: 'Switchtherapie'

Nederlands Tijdschrift voor Geneeskunde

Volumn 143, Issue 47, 1999, Pages 2364-2369

  Sevinc F ^a   Prins, J M ^a   Koopmans, R P ^a   Langendijk, P N J ^a   Dankert, J ^a   Speelman, P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFIXIME; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FLUCLOXACILLIN; FLUCONAZOLE; GENTAMICIN; ITRACONAZOLE; METRONIDAZOLE; PENICILLIN G; PHENETICILLIN; TOBRAMYCIN;

ARTICLE; COST CONTROL; DRUG ADMINISTRATION; DRUG COST; DRUG HALF LIFE; DRUG USE; FOOD DRUG INTERACTION; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALABSORPTION; ORAL DRUG ADMINISTRATION; TREATMENT CONTRAINDICATION;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; HUMANS; INFECTION; INJECTIONS, INTRAVENOUS; NETHERLANDS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 0033589713     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996;124:884-90.
2. Sevinç F, Prins JM, Koopmans RP, Langendijk PNJ, Bossuyt PMM, Dankert J, et al. Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital. J Antimicrob Chemother 1999;43:601-6.
3. Sevinç F, Prins JM, Koopmans RP, Langendijk PNJ, Bossuyt PMM, Dankert J, et al. Vroege omzetting van intraveneuze naar orale antibiotica bevorderd door invoering van een richtlijn in een opleidingsziekenhuis. Ned Tijdschr Geneeskd 1999;143:2370-4.
4. Mandell LA, Bergeron MG, Gribble MJ, Jewesson PJ, Low DE, Marrie TJ, et al. Sequential antibiotic therapy: effective cost management and patient care. Canadian Journal of Infectious Diseases 1995;6:306-15.
5. MacGregor RR, Graziani AL. Oral administration of antibiotics: a rational alternative to the parenteral route. Clin Infect Dis 1997;24:457-67.
6. Hamilton-Miller JMT. Switch therapy: the theory and practice of early change from parenteral to non-parenteral antibiotic administration. Clinical Microbiology and Infection 1996;2:12-9.
7. Gyssens IC, Lennards CA, Hekster YA, Meer JWM van der. Cost of hospital antimicrobial chemotherapy. A method for global cost calculation. Pharm Weekbl Sci 1991;13:248-53.
8. Centrale Medisch Pharmaceutische Commissic van de Ziekenfondsraad. Farmacotherapeutisch kompas 1998. Amstelveen: Ziekenfondsraad; 1998.
9. Speight TM, Holford NHG, editors. Drug treatment. 4th ed. Auckland: Adis; 1997.
10. Informatorium medicamentorum 1999. 's-Gravenhage: Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie: 1999.
11. Welling PG. Interactions affecting drug absorption. Clin Pharmacokinet 1984;9:404-34.
12. Greiff JMC, Rowbotham D. Pharmacokinctic drug interactions with gastrointestinal motility modifying agents. Clin Pharmacokinet 1994; 27:447-61.
13. Gubbins PO, Bertch KE. Drug absorption in gastrointestinal disease and surgery. Clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1991;21:431-47.
14. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-47.
15. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997;9 Suppl 3:38-44.
16. Khan FA, Basir R. Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. Chest 1989;96:528-37.
17. Regnier B. Etude comparative du céfixime en relais oral de la ceftriaxone intraveineuse versus ceftriaxone seule dans le traitement des infections urinaires hautes sévères. Presse Méd 1989;18:1617-21.
18. Paladino JA, Sperry HE, Backes JM, Gelber JA, Serrianne DJ, Cumbo TJ, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991;91:462-70.
19. Vogel F. Efficacy and tolerance of cefotaxime followed by oral cefixime versus cefotaxime alone in patients with lower respiratory tract infections. The multicenter trial group. Current Therapeutic Research 1994;55(Suppl A):42-8.
20. Kalager T, Andersen BM, Bergan T, Brubakk O, Bruun JN, Døskeland B, et al. Ciprofloxacin versus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety. Scand J Infect Dis 1992;24:637-46.
21. Gaut PL, Carron WC, Ching WTW, Meyer RD. Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections. Am J Med 1989;87(Suppl 5A):169S-75S.
22. Fass RJ, Plouffe JF, Russell JA. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. Am J Med 1989;87(Suppl 5A):164S-8S.
23. Cox CE. Sequential intravenous and oral ciprofloxacin versus intravenous ceftazidime in the treatment of complicated urinary tract infections. Am J Med 1989;87(Suppl 5A):157S-9S.
24. Dominguez J, Palma F. Vega ME, Magana JL, Ortiz G, Teresa-Hojyo M, et al. Prospective. controlled, randomized non-blind comparison of intravenous/oral ciprofloxacin with intravenous ceftazidime in the treatment of skin or soft-tissue infections. Am J Med 1989;87(Suppl 5A):136S-7S.
25. Amodio-Groton M, Madu A, Madu CN, Briceland LL, Seligman M, McMaster P, et al. Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis. Ann Pharmacother 1996;30:596-602.
26. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient iv. antibiotics tor community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965-71.
27. Gangji D, Jacobs F, Jonckheer J de, Coppens L, Serruys E, Hanotte F, et al. Randomized study of intravenous versus sequential intravenous/oral regimen of ciprofloxacin in the treatment of gramnegative septicemia. Am J Med 1989;87(Suppl 5A):206S-8S.
28. Chan R, Hemeryck L, O'Regan M, Clancy L. Feely J. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. BMJ 1995;310:1360-2.
29. Dagan R, Syrogiannopoulos G, Ashkenazi S, Engelhard D, Einhorn M, Gatzola-Karavelli M, et al. Parenteral-oral switch in the management of paediatric pneumonia. Drugs 1994;47 Suppl 3:43-51.
30. Vogel F. Sequential therapy in the hospital management of lower respiratory infections. Am J Med 1995;99 Suppl 6B:14S-9S.
31. Niederman MS, Bass jr JB, Campbell GD, Fein AM, Grossman RF, Mandell LA, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Resp Dis 1993; 148:1418-26.
32. Mandell LA. Sequential antibiotic therapy. Neth J Med 1997;50:93-6.
33. Seto WH, Ching TY, Kou M, Chiang SC, Lauder IJ, Kumana CR. Hospital antibiotic prescribing successfully modified by 'immediate concurrent feedback'. Br J Clin Pharmacol 1996;41:229-34.
34. Okpara AU, Maswoswe JJ, Stewart K. Criteria-based antimicrobial iv to oral conversion program. Formulary 1995;30:343-8.
35. Frighetto L, Nickoloff D, Martinusen SM, Mamdani FS, Jewesson PJ. Intravenous-to-oral stepdown program: four years of experience in a large teaching hospital. Ann Pharmacother 1992;26:1447-51.
36. Hunter KA, Dormaier GK. Pharmacist-managed intravenous to oral step-down program. Clin Ther 1995;17:534-40.
37. Allen B. Naismith NW, Manser AJ, Moulds RFW. A campaign to improve the timing of conversion from intravenous to oral administration of antibiotics. Australian Journal of Hospital Pharmacy 1992; 22:434-9.
38. Ahkee S, Smith S, Newman D, Ritter W, Burke J, Ramirez JA. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: a 6-month prospective study. Pharmacotherapy 1997; 17:569-75.
39. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995;155:1273-6.
40. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3271-7.
41. Malfair SC, Frighetto L, Nickoloff DM, Martinusen SM, Jewesson PJ. Evaluation of the use of cefuroxime and celuroxime axetil in an intravenous-oral stepdown program. Ann Pharmacother 1996;30: 337-42.
42. Shepherd MF, Giese RM, Making the switch from i.v. to p.o. [letter]. Am J Hosp Pharm 1994;51:2510.
43. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxonc to oral cefpodoxime proxetil. Ann Pharmacother 1995;29: 561-5.